These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7166171)

  • 1. Evaluation and comparison of hemocoagulation parameters both in serum and in ascites from patients with gynecologic malignancies.
    Varcaccio-Garofalo G; Selvaggi L; Capozza G; Orlando E; Ferreri R; Restaino A
    Eur J Gynaecol Oncol; 1982; 3(2):113-4. PubMed ID: 7166171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
    Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
    Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis.
    Hafter R; Klaubert W; Gollwitzer R; von Hugo R; Graeff H
    Thromb Res; 1984 Jul; 35(1):53-64. PubMed ID: 6474409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Paternoster A; Pengo V; Marchesoni D
    Clin Exp Obstet Gynecol; 1981; 8(2):64-5. PubMed ID: 7199979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Pengo V; Marchesoni D
    Eur J Gynaecol Oncol; 1981; 2(3):127-8. PubMed ID: 7347682
    [No Abstract]   [Full Text] [Related]  

  • 6. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D dimer using EIA and latex test.
    Hafter R; Schröck R; von Hugo R; Graeff H
    Scand J Clin Lab Invest Suppl; 1985; 178():137-44. PubMed ID: 3867114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fibrinogen degradation products in gynecologic neoplasms].
    Tatra G; Breitenecker G; Karsai I
    Fortschr Med; 1976 May; 94(13):752-4. PubMed ID: 955534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coagulant and procoagulant factors in ascitic fluid--about etiology DIC induced by ascitic fluid infusion (author's transl)].
    Ojiro M
    Igaku Kenkyu; 1981 Oct; 51(4):177-85. PubMed ID: 7331734
    [No Abstract]   [Full Text] [Related]  

  • 9. Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.
    Thaler J; Lisman T; Quehenberger P; Hell L; Schwabl P; Scheiner B; Bucsics T; Nieuwland R; Ay C; Trauner M; Pabinger I; Reiberger T; Mandorfer M
    Thromb Haemost; 2022 Mar; 122(3):353-362. PubMed ID: 34020489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of ascitic fluid FDP and fibrinolytic activity assay].
    Lu XG; Chen CS; Ye ZY
    Zhonghua Nei Ke Za Zhi; 1987 Sep; 26(9):530-2, 565. PubMed ID: 3450474
    [No Abstract]   [Full Text] [Related]  

  • 11. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy.
    von Tempelhoff GF; Nieman F; Heilmann L; Hommel G
    Clin Hemorheol Microcirc; 2000; 22(2):107-30. PubMed ID: 10831062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin degradation products and the diagnosis of ovarian carcinoma.
    Anstey JT; Blythe JG
    Obstet Gynecol; 1978 Nov; 52(5):605-8. PubMed ID: 724180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
    Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
    Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identification of fibrinogen or fibrin degradation products in the ascitic fluid].
    Kolodie L; Detante J; Rachail M
    Nouv Presse Med; 1978 Feb; 7(8):665. PubMed ID: 417295
    [No Abstract]   [Full Text] [Related]  

  • 15. Intraperitoneal coagulation in chronic liver disease ascites.
    Hoefs J; Barnes T; Halle P
    Dig Dis Sci; 1981 Jun; 26(6):518-22. PubMed ID: 7238271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulopathy following peritoneovenous shunting.
    Schwartz ML; Swaim WR; Vogel SB
    Surgery; 1979 Jun; 85(6):671-6. PubMed ID: 377537
    [No Abstract]   [Full Text] [Related]  

  • 17. Early diagnosis of ovarian cancer.
    Popkin DR
    Can Med Assoc J; 1979 May; 120(9):1106-8. PubMed ID: 445304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hyperfibrinolytic state of liver cirrhosis: possible pathogenetic role of ascites.
    Toschi V; Rocchini GM; Motta A; Fiorini GF; Cimminiello C; Violi F; Castelli C; Sironi D; Gibelli A
    Biomed Pharmacother; 1993; 47(8):345-52. PubMed ID: 8061256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical significance of thrombin-antithrombin III complex (TAT) and fibrinogen and fibrin degradation products (FDP) levels in ovarian cancer].
    Sawaguchi K; Hojo T; Nozaki S; Yabushita H; Noguchi M; Nakanishi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jan; 44(1):73-8. PubMed ID: 1541865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
    Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
    J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.